参考文献/References:
[1] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志, 2007, 46(10): 876-882.DOI:10.3760/j.issn:0578-1426.2007.10.035 Drafting Group of the Chinese Medical Association Endocrinology Branch China.China thyroid disease treatment guidelines—hyperthyroidism[J].Chin J Intern Med, 2007, 46(10): 876-882.
[2] 中华医学会核医学分会.131I治疗格雷夫斯甲亢指南(2013版)[J].标记免疫分析与临床, 2014, 21(1):92-104.DOI:10． 11748/bjmy． issn． 1006－1703． 2014． 01． 030.Chinese Society of Nuclear Medicine.131I treatment of Graves’ hyperthyroidism Guide(2013 Edition)[J].Labeled Immunoassays & Clin Med, 2014, 21(1): 92-104.
[3] 万芳, 林秋玉, 赵红光, 等.131I治疗甲状腺功能亢进症的研究进展[J].吉林大学学报:医学版, 2013, 39(4): 851-854.DOI:10.7694/jldxyxb20130444.Wan F, Lin QY, Zhao HG, et al.Advanced research on 131I in treatment of hyperthyroidism[J].J Jilin Univ(Med Edit), 2013, 39(4): 851-854.
[4] 蒋宁一, 匡安仁, 谭建, 等.131I治疗Graves甲亢专家共识(2010年)[J].中华核医学杂志, 2010, 30(5): 346-351.DOI:10.3760/cma.j.issn.0253-9780.2010.05.019.Jiang NY, Kuang AR, Tan J, et al.131I therapy for Graves hyperthyroidism expert consensus(2010)[J].Chin J Nucl Med, 2010, 30(5): 346-351.
[5] 徐志勇, 周嘉强.131I治疗甲状腺疾病进展[J].全科医学临床与教育, 2012, 10(2): 170-172.DOI:10.3969/j.issn.1672-3686.2012.02.016.Xu ZY, Zhou JQ.131I thyroid disease progression treatment[J].Clin Edu Gen Prac, 2012, 10(2): 170-172.
[6] 张永学, 黄钢.核医学[M].2版.北京:人民卫生出版社, 2010: 209-233.Zhang YX, Huang G.Nuclear Medicine[M].2nd ed.Beijing:People’s Medical Publishing House, 2010: 209-233.
[7] 武海明, 谭天秩, 匡安仁, 等.131I治疗Graves甲亢疗效影响因素的研究[J].中华核医学杂志, 2003, 23(5): 291, 293.DOI:10.3760/cma.j.issn.2095-2848.2003.05.024.Wu HM, Tan TZ, Kuang AR, et al.131I treatment of hyperthyroidism Efficacy Study of Factors Affecting Graves[J].Chin J Nucl Med, 2003, 23(5): 291, 293.
[8] 田志远, 田丽霞, 付秀玲, 等.影响131I首次治疗甲状腺功能亢进症疗效因素分析[J].中华实用诊断与治疗杂志, 2010, 24(2): 206-207.Tian ZY, Tian LX, Fu XL, et al.Effect 131I Hyperthyroidism first treatment efficacy factors[J].J Chin Pract Diagn Ther, 2010, 24(2): 206-207.
[9] Bahn Chair RS, Burch HB, Cooper DS, et al.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J].Thyroid, 2011, 21(6): 593-646.DOI:10.1089/thy.2010.0417.
[10] 马寄晓, 刘秀杰, 何作祥.实用临床核医学[M].3版.北京:中国原子能出版社, 2012: 288-293.Ma JX, Liu XJ, He ZX.Practical clinical nuclear medicine[M].3rd ed.Beijing:China Atomic Energy Press, 2012: 288-293.
[11] 李少林, 王荣福.核医学[M].7版.北京:人民卫生出版社, 2008: 262.Li SL, Wang RF.Nuclear Medicine[M].7th ed.Beijing:People’s Medical Publishing House, 2008: 262.
[12] 傅宏亮, 杜学亮, 李佳宁, 等.计算剂量方案行格雷夫斯病甲状腺功能亢进放射性碘治疗的疗效分析[J].上海交通大学学报(医学版), 2014, 34(7): 1039-1042.DOI:10.3969/j.issn.1674-8115.2014.07.016.Fu HL, Du XL, Li JN, et al.Calculate dosage regimen row Graves’ disease hyperthyroidism radioactive iodine treatment efficacy[J].Shanghai Jiaotong Univ(Med Edit), 2014, 34(7): 1039-1042.
[13] 武海明, 谭天秩, 匡安仁, 等.131I治疗Graves甲亢近期疗效评价[J].山西医科大学学报, 2002, 33(6): 532-533.DOI:10.3969/j.issn.1007-6611.2002.06.021.Wu HM, Tan TZ, Kuang AR, et al.Short-term effects of radioiodine treatment on Graves’ hyperthyroidism[J].J Shanxi Med Univ, 2002, 33(6): 532-533.
[14] Alexander EK, Larsen PR.High dose of 131I therapy for the treatment of hyperthyroidism caused by Graves’ disease[J].J Clin Endocrinol Metab, 2002, 87(3): 1073-1077.DOI:10.1210/jcem.87.3.8333.
相似文献/References:
[1]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[2]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[3]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[4]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[5]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[6]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[7]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[8]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[9]张建媛,缪蔚冰.电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究[J].国际放射医学核医学杂志,2012,36(1):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
ZHANG Jian-yuan,MIAO Wei-bing.Comparative study between electrochemiluminescence immunoassay and radioactive receptor assay in measurement of serum thyrotropin receptor antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
[10]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[13]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[14]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[15]孙琦婷,赵德善.Graves病甲状腺功能亢进症与血糖代谢[J].国际放射医学核医学杂志,2010,34(3):143.
SUN Qi-ting,ZHAO De-shan.Graves disease hyperthyroidism and glycometabolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):143.
[16]袁卫红,张怡,罗志航.内分泌性眼病患者外周血中白细胞介素6和胰岛素样生长因子1水平变化的研究[J].国际放射医学核医学杂志,2008,32(3):167.
YUAN Wei-hong,ZHANG Yi,LUO Zhi-hang.The investigation of cytokine level in peripheral blood of patients with thyroid eye disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):167.
[17]覃伟武.131Ⅰ治疗非Graves’甲状腺功能亢进及非毒性甲状腺肿后诱发Graves’病[J].国际放射医学核医学杂志,2006,30(6):325.
QIN Wei-wu.Induction of Graves’ disease in patients with non-autoimmune hyperthyroidism or nontoxic goiter after radioiodine treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):325.
[18]赵炎,王俊起,沈婕.Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析[J].国际放射医学核医学杂志,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
Zhao Yan,Wang Junqi,Shen Jie.131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]